Drug, Pharmaceutical drug, Pharmacology, Clinical trial, Drugs, Pharmaceutical industry
Scoop: Blade Therapeutics CEO, CFO appear to depart amid 'transition' after nixed SPAC
The two top executives at Blade Therapeutics appear to no longer be with the biotech after the startup failed to merge with its SPAC partner earlier this year. The biotech’s CEO and CFO no longer list the San Francisco-based drug developer as their employer on their LinkedIn pages, and ...
Scoop: Blade Therapeutics CEO, CFO appear to depart amid 'transition' after nixed SPAC
The two top executives at Blade Therapeutics appear to no longer be with the biotech after the startup failed to merge with its SPAC partner earlier this year. The biotech’s CEO and CFO no ...
We are sorry, we could not find the related article
If you are curious about Biotech and Career and Jobs
Please click on:
Subscribe to Biotech - Career and Jobs
Say goodbye to Vallon as a low-profile NKT cell startup steps into its battered shoes on Nasdaq
Eight months after Vallon Pharmaceuticals’ late-stage shot at R&D glory ended in a short, sharp implosion with the failure of a Phase III study for its lead ADHD drug, the tiny biotech will ...
Clinical Catch-Up: New SMA and Alzheimer's Data
It was a busy week for clinical trial announcements. Here's a look.
Bio Roundup: mRNA Vaccine Data, Rise of Rallybio, Roche’s Protein Play & More
As the nation started to reopen this week following two months of closed businesses and stay-at-home orders, public health officials and economists
R&D budgets in pharma
Big Pharma companies are still, naturally, the big spenders in drug R&D, and the numbers are impressive: Last year, and for the first time, the top 15 largest companies (by sales) funneled ...
Digital therapeutics get first FDA clearance, Novartis focuses on digital after announcing job cuts and other Q4 pharma news
Also: The pharma industry continues to use digital technologies for R&D and diabetes management.